Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Obesity
- Vol. 44 (6), 1254-1263
- https://doi.org/10.1038/s41366-020-0535-5
Abstract
Background/objectives Diabetic subjects are at increased risk of subtle cognitive impairment since the disease early stages and of dementia later in life. In animal models, glucagon-like peptide-1 receptor agonizts (GLP1-RAs) have been shown to exert neuroprotective effects, expecially in the memory domain. We assessed whether treatment with a GLP1-RA might affect cognitive functions in type 2 diabetic subjects independently on the weight loss it might induce. Subjects/methods Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1.8 mg/d) (n = 20) or lifestyle counseling (dietary intervention and exercise training) (n = 20) until achieving a modest and comparable weight loss (-7% of initial body weight). Interventions/methods A detailed neuropsychological assessment before and after weight loss was completed in 16 patients per arm, who were administered a total of seven psychological tests, thus assessing three composite domain z-scores for attention, memory, and executive control. Results After comparable weight loss and superimposable glycemic control and insulin sensitivity, a significant increase in short term memory (mean Digit Span Z score from -0.06 to 0.80, p = 0.024) and memory composite z-score (mean memory z-score from -0.67 to 0.032, p = 0.0065) was observed in the liraglutide exposed subjects (between group p = 0.041 and p = 0.033, respectively). Conclusions Liraglutide might slow down memory function decline in diabetic patients in early, and possibly preclinical stages of the disease.This publication has 45 references indexed in Scilit:
- Exenatide and the treatment of patients with Parkinson’s diseaseJCI Insight, 2013
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesisBMC Neuroscience, 2012
- Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudyThe Lancet Neurology, 2011
- Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta‐analysisObesity Reviews, 2011
- Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brainJournal of Neuroscience Research, 2011
- Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic reviewEuropean Journal of Pharmacology, 2008
- Glucagon-like peptide-1 receptor is involved in learning and neuroprotectionNature Medicine, 2003
- Rey-Osterrieth complex figure: normative values in an Italian population sampleNeurological Sciences, 2002
- Assessment of β‐cell function during the oral glucose tolerance test by a minimal model of insulin secretionEuropean Journal of Clinical Investigation, 2001
- A cancellation test: its reliability in assessing attentional deficits in Alzheimer's diseasePsychological Medicine, 1992